October 4, 2021 -- BioLife Solutions has secured a deal with an undisclosed global pharmaceutical company to support that firm's regulatory and commercial launch of a new CAR T-cell therapy.
Under the terms of the deal, the pharmaceutical firm will use BioLife's CryoStor media, the evo cold-chain management platform, and SciSafe storage with Stirling UltraCold freezers.
The company's CryoStore freeze media is currently being used by Kite/Gilead, Bluebird Bio, and Bristol Myers Squibb, it said.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
